The Experts below are selected from a list of 273 Experts worldwide ranked by ideXlab platform
Abdelaziz Ghanemi - One of the best experts on this subject based on the ideXlab platform.
-
Elements toward novel therapeutic targeting of the adrenergic system.
Neuropeptides, 2014Co-Authors: Abdelaziz GhanemiAbstract:Adrenergic receptors belong to the family of the G protein coupled receptors that represent important targets in the modern pharmacotherapies. Studies on different physiological and pathophysiological properties of the adrenergic system have led to novel evidences and theories that suggest novel possible targeting of such system in a variety of pathologies and disorders, even beyond the classical known therapeutic possibilities. Herein, those advances have been illustrated with selected concepts and different examples. Furthermore, we illustrated the applications and the therapeutic implications that such findings and advances might have in the contexts of Experimental Pharmacology, therapeutics and clinic. We hope that the content of this work will guide researches devoted to the adrenergic aspects that combine neurosciences with Pharmacology.
Lara A. Ray - One of the best experts on this subject based on the ideXlab platform.
-
neuroimaging findings from an Experimental Pharmacology trial of naltrexone in heavy drinkers of east asian descent
Drug and Alcohol Dependence, 2019Co-Authors: Aaron C Lim, Spencer Bujarski, Emily E. Hartwell, Dara G Ghahremani, Erica N Grodin, Rejoyce Green, Kelly E Courtney, Kent E Hutchison, Karen Miotto, Lara A. RayAbstract:Abstract Background Despite known genetic variation across races, studies examining pharmacogenetics of a single nucleotide polymorphism (SNP) of the mu-opioid receptor gene (OPRM1) on clinical response to naltrexone have been conducted in predominantly Caucasian samples. Evidence is mixed for pharmacogenetic OPRM1 and naltrexone effects on neural responses to alcohol cues. The current study tests the pharmacogenetic effects of naltrexone and OPRM1 on neural responses to alcohol taste cues in heavy drinkers of East Asian descent. Methods Participants (N = 41) completed two double-blinded and counterbalanced functional magnetic resonance imaging (fMRI) sessions: one after taking naltrexone (50 mg/day) for four days and one after taking placebo for four days. Following titration, participants completed an fMRI alcohol taste-cues task. Analyses tested effects of naltrexone, OPRM1, and their interaction in whole-brain and region of interest (ROI) analyses of functional activation and functional connectivity in response to alcohol versus water taste cues. Results We found no effects of naltrexone orOPRM1 on neural activation in whole-brain and ROI analyses, which included left and right ventral striatum (VS), anterior cingulate cortex (ACC), and orbitofrontal cortex (OFC). Naltrexone increased functional connectivity between left VS and clusters in medial prefrontal cortex, posterior cingulate gyrus, as well as right VS and occipital cortex, compared to placebo. Conclusions Naltrexone treatment enhanced functional connectivity in a key reinforcement-related pathway during alcohol versus water taste cues, corroborating neuroimaging work with other substances. Null medication and pharmacogenetics effects on functional activation add to a mixed naltrexone literature and may underscore the modest size of these effects in East Asians.
-
Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?
The American journal of drug and alcohol abuse, 2017Co-Authors: Lara A. Ray, Spencer Bujarski, Megan M. Yardley, Daniel J. O. Roche, Emily E. HartwellAbstract:Background: Medication development for alcoholism typically includes Experimental Pharmacology studies with non-treatment-seeking individuals with alcohol use disorder (AUD) paving the way for rand...
Anton Y. Bespalov - One of the best experts on this subject based on the ideXlab platform.
-
mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?
Psychopharmacology, 2017Co-Authors: Olga A. Dravolina, Edwin Zvartau, Wojciech Danysz, Anton Y. BespalovAbstract:Modulation of the mGlu1 receptor was repeatedly shown to inhibit various phenomena associated with exposure to abused drugs. Efficacy in preclinical models was observed with both positive and negative allosteric modulators (PAMs and NAMs, respectively) using essentially non-overlapping sets of Experimental methods. Taken together, these data indicate that the mGlu1 receptor certainly plays a significant role in the plasticity triggered by the exposure to abused drugs and is involved in the maintenance of drug-seeking and drug-taking behaviors. Understanding whether modulation of the mGlu1 receptor activity can also affect drug-seeking and drug-taking in humans could have a significant impact on the future development of medications in this field. We argue that the mGlu1 receptor NAMs have a significant value as potential tools for human Experimental Pharmacology that could help to validate methods used in preclinical research. Compared with the PAMs, the mGlu1 receptor NAMs appear to be better candidates for this role due to the following: (1) a number of highly potent, selective, and chemically diverse mGlu1 receptor NAMs to choose from; (2) availability of high-quality PET ligands to monitor target exposure; and (3) a rich pharmacological profile with a number of effects that can complement anti-addictive action (e.g., anxiolytic/antidepressant) and may also serve as additional pharmacodynamic readouts during the preclinical-to-clinical translation. We believe that the mGlu1 receptor NAMs have a significant value as potential tools for human Experimental Pharmacology that could help to validate methods used in preclinical research.
Ao Ying - One of the best experts on this subject based on the ideXlab platform.
-
Some thought on the reformation of teaching Experimental Pharmacology
Journal of Shanxi Medical University, 2004Co-Authors: Ao YingAbstract:Pharmacology is a theoretical as well as an Experimental science. In order to foster qualified talents, some measures should be taken in the Experimental education for the purposes of: to rationally set the Experimental program, to rationally arrange the Experimental sequence, to develop designing experiments, to open laboratories, to try different teaching methods, to correlate clinical practice and shorten the distance between basic teaching and clinical practice.
Sonia Do Carmo - One of the best experts on this subject based on the ideXlab platform.
-
Experimental Pharmacology in transgenic rodent models of alzheimer s disease
Frontiers in Pharmacology, 2019Co-Authors: Claudio A. Cuello, Hélène Hall, Sonia Do CarmoAbstract:This Mini Review discusses the merits and shortfalls of transgenic (tg) rodents modeling aspects of the human Alzheimer's disease (AD) pathology and their application to evaluate Experimental therapeutics. It addresses some of the differences between mouse and rat tg models for these investigations. It relates, in a condensed fashion, the experience of our research laboratory with the application of anti-inflammatory compounds and S-adenosylmethionine (SAM) at the earliest stages of AD-like amyloid pathology in tg mice. The application of SAM was intended to revert the global brain DNA hypomethylation unleashed by the intraneuronal accumulation of amyloid-β-immunoreactive material, an intervention that restored levels of DNA methylation including of the bace1 gene. This review also summarizes Experimental Pharmacology observations made in the McGill tg rat model of AD-like pathology by applying "nano-lithium" or a drug with allosteric M1 muscarinic and sigma 1 receptor agonistic properties (AF710B). Extremely low doses of lithium (up to 400 times lower than used in the clinic) had remarkable beneficial effects on lowering pathology and improving cognitive functions in tg rats. Likewise, AF710B treatment, even at advanced stages of the pathology, displayed remarkable beneficial effects. This drug, in Experimental conditions, demonstrated possible "disease-modifying" properties as pathology was frankly diminished and cognition improved after a month of "wash-out" period. The Mini-Review ends with a discussion on the predictive value of similar Experimental pharmacological interventions in current rodent tg models. It comments on the validity of some of these approaches for early interventions at preclinical stages of AD, interventions which may be envisioned once definitive diagnosis of AD before clinical presentation is made possible.
-
Experimental Pharmacology in Transgenic Rodent Models of Alzheimer’s Disease
Frontiers Media S.A., 2019Co-Authors: Claudio A. Cuello, Hélène Hall, Sonia Do CarmoAbstract:This Mini Review discusses the merits and shortfalls of transgenic (tg) rodents modeling aspects of the human Alzheimer’s disease (AD) pathology and their application to evaluate Experimental therapeutics. It addresses some of the differences between mouse and rat tg models for these investigations. It relates, in a condensed fashion, the experience of our research laboratory with the application of anti-inflammatory compounds and S-adenosylmethionine (SAM) at the earliest stages of AD-like amyloid pathology in tg mice. The application of SAM was intended to revert the global brain DNA hypomethylation unleashed by the intraneuronal accumulation of amyloid-β-immunoreactive material, an intervention that restored levels of DNA methylation including of the bace1 gene. This review also summarizes Experimental Pharmacology observations made in the McGill tg rat model of AD-like pathology by applying “nano-lithium” or a drug with allosteric M1 muscarinic and sigma 1 receptor agonistic properties (AF710B). Extremely low doses of lithium (up to 400 times lower than used in the clinic) had remarkable beneficial effects on lowering pathology and improving cognitive functions in tg rats. Likewise, AF710B treatment, even at advanced stages of the pathology, displayed remarkable beneficial effects. This drug, in Experimental conditions, demonstrated possible “disease-modifying” properties as pathology was frankly diminished and cognition improved after a month of “wash-out” period. The Mini-Review ends with a discussion on the predictive value of similar Experimental pharmacological interventions in current rodent tg models. It comments on the validity of some of these approaches for early interventions at preclinical stages of AD, interventions which may be envisioned once definitive diagnosis of AD before clinical presentation is made possible
